Literature DB >> 16412077

The outcome of surgery in fulminant Clostridium difficile colitis.

K Koss1, M A Clark, D S A Sanders, D Morton, M R B Keighley, J Goh.   

Abstract

BACKGROUND: The clinical presentation of Clostridium difficile infection ranges from asymptomatic carriage, colitis with or without pseudomembranes, to fulminant colitis. Although not common, fulminant C. difficile colitis can result in bowel perforation and peritonitis with a high mortality rate. Colectomy is often indicated in these cases.
METHODS: We retrospectively analysed the outcome of 14 patients who underwent surgery for fulminant C. difficile colitis in the period 1996-2003 in our Unit.
RESULTS: The indications for surgery were systemic toxicity and peritonitis (n = 10), radiological and clinical evidence of progressive toxic colonic dilatation (n = 3) and progressive colonic dilatation with bowel perforation (n = 1). C. difficile infection as the cause of colitis was diagnosed pre-operatively in seven (50%) patients, six of whom underwent a total colectomy and one a right hemicolectomy. Overall mortality in our series was 35.7%. Total colectomy was associated with a lower mortality rate of 11.1% (1/9) when compared with left hemicolectomy was 100% (4/4) (P = 0.01). One patient who underwent a right hemicolectomy (on the basis of deceptively normal external appearance of the rest of the colon intra-operatively) survived after a prolonged hospital stay.
CONCLUSIONS: Early or pre-operative microbiological diagnosis of C. difficile infection can be difficult in patients with a fulminant presentation. Those patients with C. difficile colitis, who develop signs of toxicity, peritonitis or perforation, should undergo a total colectomy as the operation of choice.

Entities:  

Mesh:

Year:  2006        PMID: 16412077     DOI: 10.1111/j.1463-1318.2005.00876.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  33 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Evolving Strategies to Manage Clostridium difficile Colitis.

Authors:  Jessica A Bowman; Garth H Utter
Journal:  J Gastrointest Surg       Date:  2019-11-25       Impact factor: 3.452

Review 3.  Epidemiology, pathogenesis, and management of Clostridium difficile infection.

Authors:  Rajaraman Durai
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

Review 4.  Surgical Management of Clostridium difficile Colitis.

Authors:  Ann K Seltman
Journal:  Clin Colon Rectal Surg       Date:  2012-12

5.  Comparison of Outcomes Between Total Abdominal and Partial Colectomy for the Management of Severe, Complicated Clostridium Difficile Infection.

Authors:  David Peprah; Alexander S Chiu; Raymond A Jean; Kevin Y Pei
Journal:  J Am Coll Surg       Date:  2018-12-18       Impact factor: 6.113

Review 6.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 7.  The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly.

Authors:  Yao-Wen Cheng; Monika Fischer
Journal:  Curr Treat Options Gastroenterol       Date:  2017-09

Review 8.  Pseudomembranous colitis.

Authors:  Priya D Farooq; Nathalie H Urrunaga; Derek M Tang; Erik C von Rosenvinge
Journal:  Dis Mon       Date:  2015-03-11       Impact factor: 3.800

9.  Emergency subtotal colectomy for fulminant Clostridium difficile colitis--is a surgical solution considered for all patients?

Authors:  K Gash; E Brown; A Pullyblank
Journal:  Ann R Coll Surg Engl       Date:  2010-01       Impact factor: 1.891

10.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.